Literature DB >> 33659314

Methodology for in vitro Assessment of Human T Cell Activation and Blockade.

Joseph R Podojil1, Igal Ifergan1, Ming-Yi Chiang1, Joshua J Meeks2,3, Stephen D Miller1,4.   

Abstract

Methods to test both the functionality and mechanism of action for human recombinant proteins and antibodies in vitro have been limited by multiple factors. To test the functionality of a recombinant protein or antibody, the receptor, the receptor-associated ligand, or both must be expressed by the cells present within the in vitro culture. While the use of transfected cell lines can circumvent this gap, the use of transfected cell lines does not allow for studying the native signaling pathway(s) modulated by the specific recombinant protein or antibody in primary cells. The present protocol utilizes sort purified CD14+ monocytes and T cells, both CD4+ T cells and CD8+ T cells, from healthy donors in a co-culture system. This methodology is particularly relevant for testing recombinant proteins or antibodies that are putative therapeutics for the treatment of autoimmune disease and cancer. While the current protocol focuses on co-cultures containing B7-H4 expressing monocytes plus either autologous CD4+ T cells or CD8+ T cells, the protocol can be modified for the user's specific needs.
Copyright © 2020 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Human CD14+ monocytes ; Human CD4+ T cells ; Human CD8+ T cells ; B7-H4; Co-culture; PBMCs

Year:  2020        PMID: 33659314      PMCID: PMC7842510          DOI: 10.21769/BioProtoc.3644

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  10 in total

1.  Host b7x promotes pulmonary metastasis of breast cancer.

Authors:  Yael M Abadi; Hyungjun Jeon; Kim C Ohaegbulam; Lisa Scandiuzzi; Kaya Ghosh; Kimberly A Hofmeyer; Jun Sik Lee; Anjana Ray; Claudia Gravekamp; Xingxing Zang
Journal:  J Immunol       Date:  2013-03-01       Impact factor: 5.422

2.  B7-H4 expression in various tumors determined using a novel developed monoclonal antibody.

Authors:  Yun Qian; Ling Shen; Linfang Cheng; Zhigang Wu; Hangping Yao
Journal:  Clin Exp Med       Date:  2010-12-29       Impact factor: 3.984

3.  The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation.

Authors:  Susana Salceda; Tenny Tang; Muriel Kmet; Andrei Munteanu; Malavika Ghosh; Roberto Macina; Wenhui Liu; Glenn Pilkington; Jackie Papkoff
Journal:  Exp Cell Res       Date:  2005-05-15       Impact factor: 3.905

4.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

5.  B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.

Authors:  Iris Simon; Dionyssios Katsaros; Irene Rigault de la Longrais; Marco Massobrio; Andreas Scorilas; Nam W Kim; Mark J Sarno; Robert L Wolfert; Eleftherios P Diamandis
Journal:  Gynecol Oncol       Date:  2007-05-11       Impact factor: 5.482

6.  B7-H4Ig inhibits mouse and human T-cell function and treats EAE via IL-10/Treg-dependent mechanisms.

Authors:  Joseph R Podojil; Linda N Liu; Shannon A Marshall; Ming-Yi Chiang; Gwen E Goings; Lieping Chen; Solomon Langermann; Stephen D Miller
Journal:  J Autoimmun       Date:  2013-05-14       Impact factor: 7.094

7.  Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity.

Authors:  Joyce Wei; P'ng Loke; Xingxing Zang; James P Allison
Journal:  J Exp Med       Date:  2011-07-04       Impact factor: 14.307

8.  Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Authors:  Matthew M Gubin; Xiuli Zhang; Heiko Schuster; Etienne Caron; Jeffrey P Ward; Takuro Noguchi; Yulia Ivanova; Jasreet Hundal; Cora D Arthur; Willem-Jan Krebber; Gwenn E Mulder; Mireille Toebes; Matthew D Vesely; Samuel S K Lam; Alan J Korman; James P Allison; Gordon J Freeman; Arlene H Sharpe; Erika L Pearce; Ton N Schumacher; Ruedi Aebersold; Hans-Georg Rammensee; Cornelis J M Melief; Elaine R Mardis; William E Gillanders; Maxim N Artyomov; Robert D Schreiber
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

9.  Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma.

Authors:  Joseph R Podojil; Alexander P Glaser; Dylan Baker; Elise T Courtois; Damiano Fantini; Yanni Yu; Valerie Eaton; Santhosh Sivajothi; Mingyi Chiang; Arighno Das; Kimberly A McLaughlin; Paul Robson; Stephen D Miller; Joshua J Meeks
Journal:  Oncoimmunology       Date:  2020-04-16       Impact factor: 8.110

10.  Comparison of T cell receptor-induced proximal signaling and downstream functions in immortalized and primary T cells.

Authors:  Rebekah R Bartelt; Noemi Cruz-Orcutt; Michaela Collins; Jon C D Houtman
Journal:  PLoS One       Date:  2009-05-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.